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Abstract
Objectives: Discounting of costs in health-related economic evaluation is generally regarded as uncon-
troversial, but there is disagreement about discounting health benefits. We sought to explore the current
recommendations and practice in health economic evaluations with regard to discounting of costs and
benefits.
Methods: Recommendations for best practice on discounting for health effects as set out by government
agencies, regulatory bodies, learned journals, and leading health economics texts were surveyed. A
review of a sample of primary literature on health economic evaluations was undertaken to ascertain
the actual current practice on discounting health effects and costs.
Results: All of the official sources recommended a positive discount rate for both health effects and
costs, and most recommended a specific rate (range, 1% to 8%). The most frequently specified rates
were 3% and 5%.
A total of 147 studies were reviewed; most of these used a discount rate for health of either 0% (nD 50)
or 5% (n D 67). Over 90% of studies used the same discount rate for both health and cost. While 28%
used a zero rate for both health and cost, in 64% a nonzero rate was used for both. Studies where the
health measure was in natural clinical units (direct) were significantly more likely to have a zero discount
rate.
Conclusion: The finding that 28% of studies did not discount costs or benefits is surprising and concern-
ing. A lower likelihood of discounting for benefits when they are in natural units may indicate confusion
regarding the rationale for discounting health effects.
Keywords: Discounting, Economics, Health effects, Time preference
Discounting, the practice of weighting future gains and losses less heavily than those that
occur in the present, is a common practice in economic evaluations. The discounting of
costs in health-related economic evaluations is generally regarded as being uncontroversial,
but more disagreement exists for discounting of health benefits (13). With both costs and
benefits there is disagreement about the appropriate rate (or rates) to use and whether the
same rate should be used for both.
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to the National Primary Care Research and Development. The views expressed are not necessarily those of the
funders. At the time this work was carried out, Dave Smith was a Visiting Research Fellow at the Centre for Health
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Discounting in healthcare interventions
We sought to investigate whether the methodologic debate about discounting health
effects at the same rate as costs was reflected in official recommendations and in actual
practice. We surveyed the literature regarding recommendations for best practice on dis-
counting for health as set by government agencies, regulatory bodies, learned journals, and
leading health economics texts. We reviewed a sample of the primary literature on health
economic evaluations to ascertain the current practice on discounting health effects and
costs. We wished to see if practice was in line with the recommendations, to examine the
extent of the consensus among practitioners on discounting, and to determine if differences
in practice were systematic.
METHODS
Literature on Recommendations for Discounting
We sought to locate recommendations from the primary literature and textbooks, official
and semi-official sources, and government bodies. A literature search was undertaken to
identify a range of potential advice using electronic databases (MEDLINE, HealthStar,
EconLit, EMBase). A request was also posted to an international health economics mailing
list, subscribed to principally by researchers working in economic evaluation in health care.
The request asked for references concerning discount rates for health effects from official
bodies, texts, handbooks, and guidelines.
Literature Discounting Practice
We drew on the studies abstracted in an existing database of published evaluations: the
National Health Service Economic Evaluation Database (NHS EED), a database funded by
the U.K. NHS (http://nhscrd.york.ac.uk/welcome.html). The NHS EED is maintained by the
Centre for Reviews and Dissemination (CRD) and was commissioned by the Department of
Health “to develop and maintain a database of critical abstracts of economic evaluations of
health care” (5). Potential articles selected for inclusion are found by standardized electronic
and hand searches.
We included studies only when the time horizon for costs and benefits exceeded 18
months; over 96% of studies included had a time horizon of 2 years or greater. We se-
lected from the studies included in the database between 1992 and 1998. Since the type
of health effect measure used in the study (volume or value) could have implications for
the discounting procedure, we wanted a sample with a range of health outcome measures.
The preponderance of studies in the database are cost-effectiveness studies, with a smaller
number of cost utility and cost benefit studies. We accordingly selected all the cost benefit
studies and cost utility studies included in the 1992–98 database and the first 15 (by acces-
sion number) of the cost-effectiveness studies in each year. The following information was
collected from each abstract in the database: accession number, country of origin, date of
publication, discount rate (and range) for health and cost, journal, health measure, disease,
type of intervention, time horizon, and average age of study population. When a specific
discount rate for health effects or cost was not reported in the abstract, we obtained the
original article to determine whether discounting had been carried out. In cases where no
discounting was mentioned in the original article, it was assumed that none had been carried
out (i.e., rate D 0%). The discount rates reported here are the rates used in the base case. It
should be noted that no studies with a zero discount rate (on health or costs) used a positive
rate in a sensitivity analysis.
We also collected information on the impact factor for each journal where the articles
were published. The journal impact factor is a measure of the frequency with which the
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average article in a journal has been cited in a particular year and is a gauge of a journal’s
relative importance, especially compared with other journals in the same field.
The type of health effect measure was also recorded according to four categories: a)
cost benefit analysis (CBA); b) adjusted survival; c) survival; and d) direct health measure.
In the CBA analyses, health gains were measured in monetary units. The adjusted survival
category included, for example, quality-adjusted life-years (QALYs), while simple survival
used life-years gained. Direct health measures are those that use some sort of natural clinical
measure of effect without conversion to survival (e.g., decrease in milligrams per deciliters
of HDL cholesterol).
RESULTS
Literature on Recommendations for Discounting
We identified 16 different sources, displayed in Table 1. Eight are guidelines for pharma-
ceuticals, five are from government agencies, three are textbooks, and one is from a journal
(some sources fit into more than one category). These official and semi-official publications
contained little detailed discussion of the rationale for discounting and for the specific rates
recommended. Most seemed to be aimed at cost-effectiveness rather than CBA. Most con-
fined themselves to the assertion that discounting was appropriate for health interventions
to reflect the fact that future costs and benefits were less valuable. As might be expected, the
more academic sources were more likely to discuss the rationale for their recommendations.
For example, the chapter on discounting in the volume (13) produced for the U.S. Public
Health Service by a team of expert practitioners has a very full discussion of the arguments
for and against discounting health effects at the same rate as costs.
All of the sources recommend a positive discount rate for both health effects and costs.
Most (13 of 16) recommend a specific rate or range of rates, and eight suggest including
a zero rate in the analysis. The range of positive rates is between 1% and 8%. The most
frequently specified rates are 3% and 5%. Recognition of the difficulties in determining the
“correct” rate led most sources to recommend that sensitivity analysis be conducted using
a range of discount rates. None of the sources recommended that the rate should depend
on the length of the time horizon. Only one source (9) recommended that a lower discount
rate be used for health effects.
Literature on Actual Practice of Discounting
In all, 147 articles were selected for analysis (for a full listing, see reference 18). Most
studies were from the United States (n D 83, 57%), followed by the United Kingdom (n D
24, 16%) and Canada (n D 10, 7%). Table 2 shows the distribution of discount rates used
in the 147 articles reviewed. Most studies used a base discount rate for health of either 0%
(35% of studies) or 5% (47% of studies), with 10% of studies using a 3% rate for health.
Over 90% of studies used the same discount rate for both health and cost, and 28% used a
zero rate for both health and cost. It is interesting to note that none of the publications from
the United Kingdom followed the U.K. Department of Health (9) recommendation to use a
lower discount rate for health.
A logistic regression was also carried out. Studies where the health measure was in
natural clinical units (direct) were significantly less likely to have a nonzero discount rate.
Those studies with a nonzero discount rate for cost were more likely to have a nonzero
discount rate. No other factors included (country, year of publication, health measure, impact
factor of journal) in the analysis were shown to be associated with a nonzero discount rate
for health benefits.
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Discounting in healthcare interventions
Table 2. Base Case Discount Rates in Articles in Review
Health Cost
Rate n (%) n (%)
0% 50 (35) 43 (30)
2% 1 (<1) 1 (<1)
3% 14 (10) 17 (12)
4% 4 (3) 4 (3)
5% 67 (47) 69 (48)
6% 7 (5) 8 (6)
7% 1 (<1) 1 (<1)
Same rate
Both zero 40 (28)
Both nonzero 95 (64)
Different rates
Cost zero, health nonzero 3 (2)
Cost nonzero, health zero 9 (6)
DISCUSSION
Only one source (9), produced by the English Department of Health, recommends a different
rate for health effects and costs. Here the recommendation is a 6% discount rate for costs
and a 1.5% to 2% rate for the volume of health effects. The justification is the growth in the
value of future health effects and is supported by references to the earlier Treasury guidance
on economic appraisal (14) and to the paper by Parsonage and Neuburger (17), who were
economic advisors at the Department of Health and the Treasury.
The chapter by Lipscomb, Weinstein, and Torrance in the volume commissioned by
the U.S. Public Health Service (13) notes the possibility of increases in the future value
of health and suggests that they could be taken account of in a cost-effectiveness analysis
by adjusting the discount rate or the volume of health effects. The chapter notes that no
evaluations appeared to have followed this practice, and our sample of evaluations discussed
previously also found no examples. Lipscomb et al. appear to downplay the significance of
increases in the future value of health in their final recommendations. They state that they
believe that the case for adjusting health effects to allow for the growth in their future value
has yet to be fully made, although they do not provide any direct arguments against doing so.
There is some consensus in discounting practice in health economics evaluations: health
effects are discounted at the same rate as costs in over 90% of the studies in our sample. The
majority view in the methodologic literature is reflected by practitioners. There was far less
consensus on the discount rate. Base case discount rates varied between 0% and 7%, with
0%, 3%, and 5% being most prominent. Surprisingly, 30% of our sample did not discount
costs. This is clearly at variance with the recommendations surveyed previously and with
nearly all the methodologic literature.
The majority “official” view, as evidenced by the recommendations examined, is that
the cost and health consequences of interventions should be discounted at the same positive
rate, and that evaluators should undertake sensitivity analysis to examine whether the results
of evaluations are affected by assumptions about the discount rate. Most of the sources seem
to be concerned with cost-effectiveness studies and therefore with discounting the volume
of health effects. None of the majority recommendations makes any distinction between
discounting the value of health effects and the volume of health effects.
We investigated the possible determinants of the choice of discounting procedures in
the studies by multiple regression. Because the large majority of studies used the same rate
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for cost and health effects, we could not examine the factors correlated with the decision
to use the same or different rates. There was sufficient variation in the choice of discount
rate for health to enable us to conduct a logistic regression analysis of the decision to use
a positive versus a zero discount rate. The analysis showed that studies that use a direct
form of health measure are less likely to discount health effects (p < :01). This finding is
independent of whether costs have been discounted. There is thus an indication that there is
some disagreement or uncertainty in the literature about whether all health effects should be
discounted. It may be that studies where the effects are left in natural units are more likely
to be undertaken by authors who feel that discounting for costs is standard practice but
do not feel that discounting benefits is justified. Alternatively, the idea of discounting, for
example, a future millimeter of mercury of blood pressure reduction, may not be intuitive,
whereas discounting a QALY is.
This finding is at odds with conventional logic in economics. While there is debate about
the “right” discount rate and whether benefits should be discounted at the same rate as costs,
it is interesting that the decision not to discount benefits is associated with measuring in
direct or natural units. This is a seemingly illogical finding given that benefits, however
measured, are subject to the same reasoning of time preference. This point of inconsistency
should be of interest to those who assist in peer reviews of journal articles and to those
who use the findings. Failing to discount future benefits has the effect of dampening the
impact of costs, potentially showing interventions to be more cost-effective than they would
otherwise appear.
The results from this report are, of course, dependent on the sample used. For identifi-
cation of studies, we used a database that aims to include a wide range of evaluations. One
potential criticism is that our sample from this database was based on the accession number.
We chose that method of selection because random sampling was logistically awkward, and
further, there was no obvious reason to suspect bias from the chosen method. These findings
should be taken in the context of the years over which the studies were performed. Over
half of the included studies were done before 1995. Although we did not find an effect of
year of publication, a larger sample size may yield different results.
POLICY IMPLICATIONS
Our findings that 28% of studies did not discount costs or benefits, where seemingly ap-
propriate, is surprising and concerning. A previous analysis by Neumann et al. (16) that
examined discounting of QALYs showed similar results. These analyses indicate that eco-
nomic evaluations in health may be in need of further methodologic rigor. There are also
implications from this work for the peer review process. There appears to be room for
improvement in the presentation and production of economic evaluations; it is incumbent
on reviewers and journal editors to be sedulous and informed in the reviewing of these
studies.
REFERENCES
1. Alban A, Keiding H, Sogaard J. Report on guidelines for socioeconomic analyses of pharmaceu-
ticals. Copenhagen: Danish Ministry of Health; 1998.
2. Assessing the effectiveness of disease and injury programs: Costs and consequences. MMWR.
1995;44:1-10.
3. Belgian Society of Pharmacoepidemiology. A proposal for methodological guidelines for eco-
nomic evaluation of pharmaceuticals, Belgium. Brussels: Belgian Society of Pharmacoepidemi-
ology (BESPE); 1995.
4. Canadian Coodinating Office for Health Technology Assessment. Guidelines for economic eval-
uation of pharmaceuticals: Canada. 2nd ed. Ottawa: Canadian Coordinating Center for Health
Technology Assessment (CCOHTA); 1997.
242 INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 17:2, 2001
Discounting in healthcare interventions
5. Centre for Reviews and Dissemination. Making cost-effectiveness information accessible: The
NHS Economic Evaluation Database Project. York: University of York; 1996.
6. College Des Economistes De La Sante. Guidelines and recommendations for French pharmaco-
economic studies; 1997.
7. Commonwealth Department of Human Services and Health. Guidelines for the pharmaceuti-
cal industry on preparation of submission to the pharmaceutical benefits advisory committee.
Canberra: Australian Government Publishing Service; 1995.
8. da Silva E, Pinto C, Sampaio C, et al. Orientacoes metodologicas para estudos de avaliacao
economica de medicamentos. Infarmed; 1998.
9. Department of Health. Policy appraisal and health. London: Department of Health; 1995.
10. Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions
to the BMJ. BMJ. 1996;313:275.
11. Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of
health care programmes. 2nd ed. Oxford: Oxford University Press; 1997.
12. Garattini L, Grilli R, Scopelliti D, Mantovani L. A proposal for Italian guidelines in pharma-
coeconomics. PharmacoEconomics. 1995;7:1-6.
13. Gold M, Siegel J, Russel L, Weinstein M. Cost effectiveness in health and medicine. New York:
Oxford University Press; 1996.
14. HM Treasury Great Britain. Economic appraisal in central government: A technical guide for
government departments. London: HMSO Publications; 1991.
15. Homedes N. The disability adjusted life year (DALY) definition, measurement and potential use.
New York: The World Bank, Human Capital Development and Operations Policy; 1995.
16. Neumann PJ, Zinner DE, Wright JC. Are methods for estimating QALYs in cost-effectiveness
analyses improving? Med Decis Making. 1997;17:402-408.
17. Parsonage M, Neuburger H. Discounting and health benefits. Health Econ. 1992;1:71-76.
18. Smith D, Gravelle H. Discounting in health economics: A review of current practice. CHE Tech-
nical Paper Series. 2000;19. Available at: http://www.york.ac.uk/inst/che/tech.htm.
19. Viscusi K. Discounting health effects for medical decisions. In: Valuing Health Care, F. Sloan ed.
New York: Press Syndicate of the University of Cambridge; 1996.
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 17:2, 2001 243
